New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides

Area of Science:

• Pharmacology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Long-acting lipoglycopeptides (LGPs), including dalbavancin and oritavancin, are potent antimicrobials effective against Gram-positive pathogens.
• Currently approved for acute bacterial skin and soft tissue infections, their pharmacokinetic profiles suggest utility in deeper, severe infections.

Purpose of the Study:

• To review current evidence on using oritavancin and dalbavancin for invasive infections.
• To identify barriers hindering optimal LGP use and knowledge gaps.
• To discuss ongoing research addressing these clinical voids.

Main Methods:

• Literature review of existing studies and clinical trial data.
• Analysis of pharmacological properties and clinical outcomes.
• Identification of challenges and future research directions.

Main Results:

• LGPs demonstrate potential for treating deep-seated infections like bloodstream and bone/joint infections.
• Their long half-lives are advantageous for avoiding prolonged therapy and catheter use.
• Barriers to optimal use and knowledge gaps remain significant.

Conclusions:

• Dalbavancin and oritavancin hold promise for treating severe Gram-positive infections, especially when multidrug-resistant bacteria are involved.
• Addressing current limitations and knowledge gaps is crucial for expanding LGP applications.
• Ongoing clinical studies aim to further define the role of LGPs in critical infections.